Glucagon is secreted into the portal vein and thus has its major physiologic action at the liver to break down glycogen. Glucagon thereby maintains hepatic glucose production during fasting and increases hepatic glucose production during stress, including the clinically important stress of hypoglycemia. Three different mechanisms proposed to stimulate glucagon secreted during hypoglycemia are discussed: (1) a stimulatory effect of low glucose directly on the alpha cell, (2) withdrawal of an inhibitory effect of adjacent beta cells, and (3) a stimulatory effect of autonomic activation.
In type 1 diabetes (T1DM), increased glucagon secretion contributes to the elevated ketones and acidosis present in diabetic ketoacidosis (DKA). It also contributes to the hyperglycemia seen with or without DKA. The glucagon response to insulin-induced hypoglycemia is impaired soon after the development of T1DM. The mediators of this impairment include loss of beta cells and loss of sympathetic nerves from the autoimmune diabetic islet.
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SYMPOSIUM
Anatomy of the Islet
Islet Alpha Cells
In humans, glucagon is secreted from the islet alpha cells, which comprise only 10% of islet volume; 80% of islet volume is composed of beta cells, which secrete insulin. In rodents, alpha cells are located on the rim or mantle of the islet, but in humans, this arrangement is more complex. 1 Nevertheless, in both species, alpha cells are located next to insulin-secreting beta cells, suggesting a local interaction.
Islet Vasculature
Pancreatic islets are supplied by individual arterioles, which divide into a tortuous capillary complex, resembling a renal glomerulus. In most species, these capillaries first supply the islet beta cells and then supply the islet alpha cells, exposing them to high concentrations of beta-cell secretory products, which tonically suppress glucagon secretion. Blood exiting the islet drains into the pancreatic vein, which, in turn, drains into the portal vein, exposing the liver to high concentrations of glucagon. Thus, not surprisingly, the liver is the site of glucagon's major physiologic actions. Modest extraction of glucagon by the liver and major dilution of hepatic vein blood by systemic blood results in low concentrations of glucagon in peripheral plasma that, in the basal state, are difficult to measure reliably.
Islet Innervation
Sympathetic and parasympathetic nerves follow arterioles into the islet, but similar to other autonomic fibers, they do not form classical synapses. Rather, they release their neuro-transmitters, norepinephrine, and acetylcholine (ACh), respectively, near islet alpha and beta cells. Immunohistochemical staining reveals moderate density sympathetic [2] [3] [4] [5] and parasympathetic [6] [7] [8] [9] innervation of the islet, suggesting important neural control of glucagon secretion. Indeed, activation of sympathetic nerves elicits a robust glucagon response, 10, 11 which is largely retained in diabetic animals despite prevailing hyperglycemia. In contrast, activation of parasympathetic nerves elicits a more modest glucagon response. 12 Both of these autonomic inputs to the islet are activated by central hypoglycemia 13, 14 and contribute to the glucagon response to hypoglycemia. 15, 16 This glucagon response is important in glucose counterregulation. 17 It is long established that the glucagon response to hypoglycemia is defective in type 1 diabetes (T1DM). 18 Evidence suggests that there are both functional and structural defects in the autonomic pathways to the islet in T1DM.
Glucagon Biosynthesis and Processing
Products of the Proglucagon Gene
Glucagon, like other polypeptide hormones, is encoded by a prepro gene. The preproglucagon gene has six exons, one of which encodes a glucagon precursor and two of which encode the precursors for glucagon-like peptide (GLP)-1 and GLP-2, respectively. 19 Although glucagon raises blood sugar, the truncated form of GLP-1 is best known for its ability to stimulate insulin release, 20 which has the opposite effect on blood sugar. Interestingly, GLP-1 and its analogs used to treat diabetes also inhibit glucagon secretion, which likely contributes to its glucose-lowering effect. Glucagon-like peptide-2 has neither of these effects but instead promotes the growth of intestinal epithelial cells. 21 The primary structure of all three hormones is highly conserved across mammals, suggesting preservation of critical biological activity.
Tissue-Specific Processing
The product of the proglucagon gene that predominates depends on the tissue from which it is released. 19 In the alpha cells of the pancreatic islet, the biologically active form released is the 29 amino acid hormone glucagon. A major proglucagon fragment is also released from the islet alpha cells. Its sequence includes both GLP-1 and GLP-2, but these sequences are flanked by amino acids that render both products biologically inactive. In the L-cells of the small and large bowel, the reverse is true. Here, GLP-1 and GLP-2 are cleaved from the proglucagon sequence in their biologically active forms and released. The remaining sequence of the proglucagon molecule is also released, but it includes amino acids that flank glucagon and render it biologically inactive. The marked tissue difference in the secreted products of the proglucagon gene is due to different posttranslational processing mediated presumably by different processing enzymes contained within the two tissues.
Effects of Glucagon
Liver Action
The major site of glucagon's physiologic action is the liver, for several reasons. First, the liver is exposed to glucagon concentrations that are two to three times higher than the levels to which other organs are exposed. Glucagon is secreted into the portal vein and partially extracted by the liver 22 before it is diluted by the glucagon-poor blood of the systemic circulation. Second, the systemic levels of endogenous glucagon are usually below those needed to affect the glucagon receptors on adipose tissue to cause lipolysis. Further, glucagon has no appreciable effect on muscle glycogenolysis. Third, portal vein glucagon levels are high enough to activate the abundant hepatic glucagon receptors. These receptors are coupled to G protein S (G s ), which activates adenylate cyclase through its alpha subunit. The resultant increase of hepatic cyclic adenosine monophosphate levels activates protein kinase A, which, in turn, phosphorylates the enzymes needed to activate liver glycogenolysis.
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Glycogenolysis versus Gluconeogenesis
Even basal levels of portal vein glucagon are sufficient to mediate three-fourths of fasting glucose production, both in large experimental animals 24 and humans. 25 However, this degree of stimulation depends on insulin levels being low, as they are in the fasting state. Although glucagon increases hepatic gluconeogenic enzymes, the contribution of gluconeogenesis to basal glucose production is usually minor in large animals and humans. Only when fasting is quite prolonged is there a substantial mobilization of the precursors required for significant gluconeogenesis. Physiologic glucagon levels have no direct role in mobilizing gluconeogenic glycerol from adipose tissue 26 and amino acids from muscle. 27 That function is served by a substantial decrease of the systemic insulin levels.
Increases of endogenous glucagon above the fasting level also potently stimulate hepatic glucose production, largely by glycogenolysis. For example, glucagon increments as little as 10 pg/ml increase hepatic glucose production by 25%. Thus changes of glucagon secretion throughout its physiologic range control hepatic glucose production throughout its physiologic range.
Duration of Effect
The effect of glucagon on hepatic glucose production has been described as "evanescent," which seems to imply a transient, rather than a sustained, effect. In fact, the hepatic glucose production response to a stepwise increase of glucagon is a rapid peak followed by a lower, but more sustained, plateau. 28 Interestingly, this is the pattern of hepatic glucose production needed to achieve a rapid but sustained increase of plasma glucose. Indeed, part of the "evanescent" effect of glucagon is due to that increase of plasma glucose and its stimulation of insulin secretion, both of which inhibit hepatic glucose production. 29 However, this classic feedback inhibition of a metabolic pathway by its end product explains only part of the evanescent effect; the majority appears to be a downregulation of the rapid intrahepatic glucagon-signaling pathway. Nonetheless, the fact that suppression of basal glucagon secretion markedly suppresses fasting glucose production 30 reinforces the view that glucagon was chronically stimulating hepatic glucose production. Indeed, the speed with which inhibition of glucagon secretion lowers hepatic glucose production is similar to the speed with which it stimulates hepatic glucose production. 31 Thus, although pulsatility in glucagon secretion can entrain hepatic glucose production, the amount of glucose released by the liver is similar, whether the glucagon is delivered in a pulsatile or constant fashion.
Glucagon Response to Hypoglycemia
Mechanism
Three different mechanisms have been proposed to mediate the alpha-cell response to hypoglycemia: (1) a direct effect of hypoglycemia to stimulate the pancreatic alpha cell, (2) release from suppression by the islet beta cell, and (3) autonomic stimulation of the islet alpha cell.
Direct Effect of Low Glucose
Although low glucose in vitro increases glucagon secretion from the isolated perfused pancreas, 32 exposing isolated alpha cells to low glucose fails to directly stimulate glucagon secretion. 33 Thus the effect of low glucose directly on the islet alpha cell does not appear to be a major mediator of the glucagon response to hypoglycemia.
Inhibitory Effect of the Islet Beta Cell
If islet beta cells tonically inhibit glucagon secretion from neighboring alpha cells, then the direct effect of low glucose to inhibit the beta cell could contribute to the glucagon response to hypoglycemia. Such an inhibitory action of endogenous insulin was originally proposed by Samols and colleagues 34 and first strongly supported by the data of Weir and associates. 35 There is other evidence that gamma amino butyric acid (GABA) 36 and zinc, 37 secreted from the islet beta cell, play similar inhibitory roles. Indeed, destruction of islet beta cells prevents low glucose media from stimulating glucagon secretion in vitro. 38 Thus the hypothesis that a "switch-off" of inhibitory beta-cell factors help stimulate glucagon secretion during hypoglycemia is supported by a variety of in vitro data.
In vivo, the evidence for a beta-cell role is mixed. Older data show that in humans without diabetes, prior partial suppression of endogenous insulin secretion before hypoglycemia did not impair the glucagon response to hypoglycemia. 39 Similarly, patients with T1DM, who presumably have markedly reduced endogenous insulin secretion, can exhibit a normal glucagon response to hypoglycemia, at least very early after diabetes onset. 39 Conversely, more recent data suggest that prior inhibition of islet beta cells impairs 40 -and prior stimulation of islet beta cells augments 41 -the glucagon response to hypoglycemia in humans without diabetes.
Stimulatory Effect of Autonomic Activation
There are three autonomic inputs to the islet alpha cell: sympathetic nerves, parasympathetic nerves, and the circulating hormone epinephrine, which is also under neural control (Figure 1) . All three autonomic inputs stimulate glucagon secretion when activated, [10] [11] [12] 42, 43 and all three are activated during hypoglycemic stress. 13, 14, [44] [45] [46] [47] Indeed, pharmacological blockade of the ganglionic neurotransmission involved in all three autonomic pathways markedly impairs the glucagon response to insulin-induced hypoglycemia (IIH) in all species islet, 61 these patients actually have a relative basal hyperglucagonemia. Subjects with type 2 diabetes, who have much less beta-cell loss, still have a relative basal hyperglucagonemia.
During Insulin-Induced Hypoglycemia
Despite this relative basal hyperglucagonemia, the glucagon response to IIH is impaired within the first year of T1DM and lost entirely several years later. 62 In contrast, the glucagon response to arginine can be normal in T1DM, 18, 63, 64 although there are reports of moderate impairments in patients when insulin is infused to achieve euglycemia. 63, 65, 66 
Beta-Cell Factors
The mechanism for the rapid loss of the glucagon response to IIH is likely multifactorial. One factor is the loss of islet beta-cell function since, in subjects with T1DM, retention of the glucagon response to IIH seems related to the retention of C-peptide secretion. 67 Further, type 2 diabetes patients have no impairment of their glucagon tested, [48] [49] [50] including primates. 51 In addition, the alternative experimental approach of surgical disruption of all three autonomic pathways produces a similar impairment of the glucagon response to IIH. 15, 50 These data suggest that the autonomic activation that accompanies marked hypoglycemia in vivo is a major mediator of the glucagon response to IIH.
The results of these studies, ablating the autonomic nervous system's input to the islet, are similar to those from studies that inhibit the central nervous system pathways that trigger the autonomic activation. Thus, lesioning the ventromedial hypothalamus (VMH) significantly impairs both autonomic activation and the glucagon response to IIH. 52 Direct application of urocortin-1 53 or insulin 54 to the VMH also impairs the glucagon response to IIH. Finally, preventing central, but not peripheral, hypoglycemia impairs the glucagon response to IIH 55 as does microdialysis of glucose into the VMH. 56 These studies demonstrate the necessity of central activation, presumably of the three autonomic pathways, for the glucagon response to hypoglycemia in animals.
Two studies suggest a similar autonomic mediation in humans without diabetes. First, repeated hypoglycemia reduces both autonomic and glucagon responses to IIH 57 in humans. Second, ganglionic blockade in humans markedly reduces the glucagon response to IIH.
58
Glucagon Secretion in Type 1 Diabetes
During Diabetic Ketoacidosis
The basal level of glucagon circulating in the systemic plasma of patients with T1DM can be markedly elevated if they present with diabetic ketoacidosis (DKA). 59 This elevated glucagon level contributes both to their marked hyperketonemia as well as their hyperglycemia. 60 This elevation of basal glucagon levels occurs despite their hyperglycemia, which, in subjects without diabetes, suppresses glucagon secretion. Two factors likely contribute to this stimulation of the islet alpha cell. The first is activation of the sympathetic nervous system secondary to the volume depletion usually present in patients with DKA. The second is their severe beta-cell loss, which removes a tonic restraint on the alpha cell.
During Insulin Treatment
In insulin-treated T1DM patients with stabilized and moderate hyperglycemia, fasting glucagon levels are usually within normal range. However, since hyperglycemia normally suppresses glucagon secretion, an effect dependent on the high levels of insulin within the response to IIH until they lose enough islet beta cells to become dependent on insulin treatment. 68 It has been proposed in the switch-off hypothesis that factors secreted from the islet beta cell (e.g., insulin, 35, 69 zinc, 37 GABA 36 ) tonically restrain basal glucagon secretion. The hypothesis posits that hypoglycemia switches off this restraint by inhibiting islet beta-cell secretion. Indeed, reproducing this tonic restraint experimentally in diabetic animals and then releasing it, concomitant with hypoglycemia, can elicit a glucagon response. 70 
Neural Factors
However, the magnitude of the glucagon response to IIH is dependent on the recognition of hypoglycemia by the brain, not the islet. For example, preventing central glucopenia, while allowing peripheral hypoglycemia, abolishes the glucagon response to IIH. 55 This central glucopenia activates the autonomic nervous system, and blocking this autonomic activation markedly impairs the majority of the glucagon response to IIH in experimental animals [48] [49] [50] 71 and humans. 58 Interestingly, data from three animal models of autoimmune diabetes 4, 5, 72 and preliminary data from humans with T1DM 73 reveal a significant loss of islet sympathetic nerves, one of the autonomic inputs that is activated by hypoglycemia 13 and which helps mediate the glucagon response to hypoglycemia. 15 Thus this early sympathetic islet neuropathy may partly explain the impaired glucagon response to IIH seen in T1DM.
Another factor to consider is the exogenous insulin that produces the hypoglycemia. Early studies in C-peptidenegative T1DM patients clearly showed that exogenous insulin can suppress glucagon responses to other secretagogues. 63 Since insulin infusions in subjects without diabetes do not produce a net inhibition of these glucagon responses, 63 the alpha cell in the insulin-deficient islet may be supersensitive to the inhibitory effects of exogenous insulin.
Other types of chronic neuropathy, such as diabetic autonomic neuropathy, can impair the epinephrine response to IIH, 74 which, with an impaired glucagon response to IIH, renders patients with T1DM vulnerable to frequent episodes of hypoglycemia. However, even in subjects without diabetes, repeated episodes of hypoglycemia can impair the epinephrine response to IIH, 57 a phenomenon called hypoglycemia-associated autonomic failure. This type of autonomic impairment also occurs during intensive insulin therapy in T1DM. 75 Hypoglycemia-associated autonomic failure is not a classical neuropathy, but rather a desensitization of the central neural pathways that initiate the autonomic response to hypoglycemia. The cortisol response to prior hypoglycemia helps mediate this central desensitization, 76 as does upregulation of brain glucose transporters. 77 Thus intensive insulin therapy in recent-onset T1DM patients may lead to impaired glucagon responses not only due to their loss of islet sympathetic nerves but also secondary to an induced autonomic dysfunction.
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